Skip to content


Jemperli (dostarlimab) is an antibody pharmaceutical. Dostarlimab was first approved as Jemperli on 2021-04-21. It has been approved in Europe to treat endometrial neoplasms. It is known to target programmed cell death protein 1.
Trade Name Jemperli
Common Name Dostarlimab
Indication endometrial neoplasms
Drug Class Monoclonal antibodies: immunomodulating
Get full access now